Progesterone receptor antagonist CDB-4124 increases depression-like behavior in mice without affecting locomotor ability

Psychoneuroendocrinology

Volumn 36, Issue 6, 2011, Pages 824-833

  Beckley, Ethan H ^a   Scibelli, Angela C ^a   Finn, Deborah A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Allopregnanolone; CDB 4124; Forced swim test; Mifepristone; Postpartum depression; Premenstrual syndrome; Progesterone receptors

Indexed keywords

MIFEPRISTONE; PROGESTERONE; PROGESTERONE RECEPTOR; TELAPRISTONE ACETATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; IMMOBILIZATION; LOCOMOTION; MOUSE; NONHUMAN; PHYSICAL CAPACITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION;

ANIMALS; DEPRESSION; DEPRESSION, POSTPARTUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FINASTERIDE; LOCOMOTION; MICE; MICE, INBRED DBA; MIFEPRISTONE; NORPREGNADIENES; PREMENSTRUAL SYNDROME; PROGESTERONE; RECEPTORS, PROGESTERONE; SINGLE-BLIND METHOD; SWIMMING;

EID: 79956320444     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.11.004     Document Type: Article

References (63)

1. Attardi B.J., Burgenson J., Hild S.A., Reel J.R. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 2004, 88:277-288.
2. Attardi B.J., Burgenson J., Hild S.A., Reel J.R., Blye R.P. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: In vitro comparison to mifepristone and CDB-2914. Mol. Cell. Endocrinol. 2002, 188:111-123.
3. Auger C.J., Jessen H.M., Auger A.P. Microarray profiling of gene expression patterns in adult male rat brain following acute progesterone treatment. Brain Res. 2006, 1067:58-66.
4. Beckley E.H., Finn D.A. Inhibition of progesterone metabolism mimics the effect of progesterone withdrawal on forced swim test immobility. Pharmacol. Biochem. Behav. 2007, 87:412-419.
5. Bekku N., Yoshimura H., Araki H. Factors producing a menopausal depressive-like state in mice following ovariectomy. Psychopharmacology 2006, 187:170-180.
6. Belelli D., Lambert J.J. Neurosteroids: endogenous regulators of the GABAA receptor. Nat. Rev. Neurosci. 2005, 6:565-575.
7. Benagiano G., Bastianelli C., Farris M. Selective progesterone receptor modulators 1: use during pregnancy. Expert Opin. Pharmacother. 2008, 9:2459-2472.
8. Benagiano G., Bastianelli C., Farris M. Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin. Pharmacother. 2008, 9:2487-2496.
9. Bethea C.L., Reddy A.P. Effect of ovarian hormones on survival genes in laser captured serotonin neurons from macaques. J. Neurochem. 2008, 105:1129-1143.
10. Bitran D., Smith S.S. Termination of pseudopregnancy in the rat produces an anxiogenic-like response that is associated with an increase in benzodiazepine receptor binding density and a decrease in GABA-stimulated chloride influx in the hippocampus. Brain Res. Bull. 2005, 64:511-518.
11. Budney A.J., Hughes J.R. The cannabis withdrawal syndrome. Curr. Opin. Psychiatry 2006, 19:233-238.
12. Chien C.H., Lai J.N., Liao C.F., Wang O.Y., Lu L.M., Huang M.I., et al. Mifepristone acts as progesterone antagonist of non-genomic responses but inhibits phytohemagglutinin-induced proliferation in human T cells. Hum. Reprod. 2009, 24:1968-1975.
13. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
14. de Chaves G., Moretti M., Castro A.A., Dagostin W., da Silva G.G., Boeck C.R., et al. Effects of long-term ovariectomy on anxiety and behavioral despair in rats. Physiol. Behav. 2009, 97:420-425.
15. Devall A.J., Liu Z.W., Lovick T.A. Hyperalgesia in the setting of anxiety: Sex differences and effects of the oestrous cycle in Wistar rats. Psychoneuroendocrinology 2009, 34:587-596.
16. Dhir A., Kulkarni S.K. Antidepressant-like effect of 17β-estradiol: Involvement of dopaminergic, serotonergic, and (or) sigma-1 receptor systems. Can. J. Physiol. Pharmacol. 2008, 86:726-735.
17. Dong E., Matsumoto K., Uzunova V., Sugaya I., Takahata H., Nomura H., et al. Brain 5α-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:2849-2854.
18. Flores B.H., Kenna H., Keller J., Solvason H.B., Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006, 31:628-636.
19. Frye C.A., Sumida K., Dudek B.C., Harney J.P., Lydon J.P., O'Malley B.W., et al. Progesterone's effects to reduce anxiety behavior of aged mice do not require actions of intracellular progestin receptors. Psychopharmacology 2006, 186:312-322.
20. Gabriel K.I., Cunningham C.L., Finn D.A. Allopregnanolone does not influence ethanol-induced conditioned place preference in DBA/2J mice. Psychopharmacology 2004, 176:50-56.
21. Galeeva A.Y., Pivina S.G., Tuohimaa P., Ordyan N.É. Involvement of nuclear progesterone receptors in the formation of anxiety in mice. Neurosci. Behav. Physiol. 2007, 37:843-848.
22. Gallo M.A., Smith S.S. Progesterone withdrawal decreases latency to and increases duration of electrified prod burial: a possible rat model of PMS anxiety. Pharmacol. Biochem. Behav. 1993, 46:897-904.
23. Gehlert S., Chang C.H., Hartlage S. Symptom patterns of premenstrual dysphoric disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders-IV. J. Womens Health 1999, 8:75-85.
24. Gonda X., Telek T., Juhász G., Lazary J., Vargha A., Bagdy G. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1782-1788.
25. Halbreich U., Endicott J., Goldstein S., Nee J. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr. Scand. 1986, 74:576-586.
26. Hewitt S.C., Korach K.S. Progesterone action and responses in the αERKO mouse. Steroids 2000, 65:551-557.
27. Hyde J.S., Mezulis A.H., Abramson L.Y. The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression. Psychol. Rev. 2008, 115:291-313.
28. Kammerer M., Taylor A., Glover V. The HPA axis and perinatal depression: A hypothesis. Arch. Womens Ment. Health 2006, 9:187-196.
29. Kessler R.C. Epidemiology of women and depression. J. Affect. Disord. 2003, 74:5-13.
30. Korte S.M., De Kloet E.R., Buwalda B., Bouman S.D., Bohus B. Antisense to the glucocorticoid receptor in hippocampal dentate gyrus reduces immobility in the forced swim test. Eur. J. Pharmacol. 1996, 301:19-25.
31. Kurtuncu M., Luka L.J., Dimitrijevic N., Uz T., Manev H. Reliability assessment of an automated forced swim test device using two mouse strains. J. Neurosci. Methods 2005, 149:26-30.
32. Li B., Suemaru K., Cui R., Araki H. Repeated electroconvulsive stimuli have long-lasting effects on hippocampal BDNF and decrease immobility time in the rat forced swim test. Life Sci. 2007, 80:1539-1543.
33. Löfgren M., Johansson I.M., Meyerson B., Turkmen S., Bäckström T. Withdrawal effects from progesterone and estradiol relate to individual risk-taking and explorative behavior in female rats. Physiol. Behav. 2009, 96:91-97.
34. Lopez-Rodriguez F., Kim J., Poland R.E. Total sleep deprivation decreases immobility in the forced-swim test. Neuropsychopharmacology 2004, 29:1105-1111.
35. Lucki I., Dalvi A., Mayorga A.J. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001, 155:315-322.
36. MacDonald P.C., Dombroski R.A., Casey M.L. Recurrent secretion of progesterone in large amounts: an endocrine/metabolic disorder unique to young women?. Endocr. Rev. 1991, 12:372-401.
37. Mazarati A., Siddarth P., Baldwin R.A., Shin D., Caplan R., Sankar R. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008, 131:2071-2083.
38. Meaden P.M., Hartlage S.A., Cook-Karr J. Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. Psychiatry Res. 2005, 134:27-36.
39. Molina-Hernández M., Tellez-Alcántara N.P., Garcia J.P., Olivera Lopez J.I., Jaramillo M.T. Anti-depressant like actions of intra-accumbens infusions of allopregnanolone in ovariectomized Wistar rats. Pharmacol. Biochem. Behav. 2005, 80:401-409.
40. Molina-Hernández M., Tellez-Alcántara N.P., Olivera-Lopez J.I., Jaramillo M.T. Olanzapine plus 17β-estradiol produce antidepressant-like actions in rats forced to swim. Pharmacol. Biochem. Behav. 2009, 93:491-497.
41. National Research Council of the National Academies Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research 2003, National Academics Press, Washington, DC.
42. Navarre B.M., Laggart J.D., Craft R.M. Anhedonia in postpartum rats. Physiol. Behav. 2010, 99:59-66.
43. Noble R.E. Depression in women. Metab. Clin. Exp. 2005, 54(Suppl. 1):49-52.
44. Payne J.L., Palmer J.T., Joffe H. A reproductive subtype of depression: conceptualizing models and moving toward etiology. Harv. Rev. Psychiatry 2009, 17:72-86.
45. Pearlstein T., Yonkers K.A., Fayyad R., Gillespie J.A. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J. Affect. Disord. 2005, 85:275-282.
46. Pinter J.H., Deep C., Park-Sarge O.-K. Progesterone receptors: expression and regulation in the mammalian ovary. Clin. Obstet. Gynecol. 1996, 39:235-242.
47. Reddy A.P., Bethea C.L. Preliminary array analysis reveals novel genes regulated by ovarian steroids in the monkey raphe region. Psychopharmacology 2005, 180:125-140.
48. Reddy D.S., O'Malley B.W., Rogawski M.A. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 2005, 48:14-24.
49. Redei E., Freeman E.W. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995, 20:267-269.
50. Rygula R., Abumaria N., Havemann-Reinecke U., Rüther E., Hiemke C., Zernig G., et al. Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. Behav. Pharmacol. 2008, 19:183-196.
51. Sadée W., Wang D., Bilsky E.J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 2005, 76:1427-1437.
52. Schmidt P.J., Nieman L.K., Grover G.N., Muller K.L., Merriam G.R., Rubinow D.R. Lack of effect of induced menses on symptoms in women with premenstrual syndrome. N. Engl. J. Med. 1991, 324:1174-1179.
53. Schneider T., Popik P. Attenuation of estrous cycle-dependent marble burying in female rats by acute treatment with progesterone and antidepressants. Psychoneuroendocrinology 2007, 32:651-659.
54. Schulz D., Aksoy A., Canbeyli R. Behavioral despair is differentially affected by the length and timing of photic stimulation in the dark phase on an L/D cycle. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1257-1262.
55. Solomon M.B., Herman J.P. Sex differences in psychopathology: of gonads, adrenals, and mental illness. Physiol. Behav. 2009, 97:250-258.
56. Steiner M., Dunn E., Born L. Hormones and mood: from menarche to menopause and beyond. J. Affect. Disord. 2003, 74:67-83.
57. Stevenson J.R., Schroeder J.P., Nixon K., Besheer J., Crews F.T., Hodge C.W. Abstinence following alcohol drinking produces depression-like behavior and reduced hippocampal neurogenesis in mice. Neuropsychopharmacology 2009, 34:1209-1222.
58. Stoffel E.C., Craft R.M. Ovarian hormone withdrawal-induced " depression" in female rats. Physiol. Behav. 2004, 83:505-513.
59. Sufka K.J., Warnick J.E., Pulaski C.N., Slauson S.R., Kim Y.B., Rimoldi J.M. Antidepressant efficacy screening of novel target in the chick anxiety-depression model. Behav. Pharmacol. 2009, 20:146-154.
60. Tasset I., Peña J., Jimena I., Feijóo M., del Carmen Muñoz M., Montilla P., et al. Effect of 17β-estradiol on olfactory bulbectomy-induced oxidative stress and behavioral changes in rats. Neuropsychiatr. Dis. Treat. 2008, 4:441-449.
61. Taylor R.N., Savouret J.F., Vaisse C., Vigne J.L., Ryan I., Hornung D., et al. Promegestone (R5020) and mifepristone (RU486) both function as progestational agonists of human glycodelin gene expression in isolated human epithelial cells. J. Clin. Endocrinol. Metab. 1998, 83:4006-4012.
62. Wu T.H., Lin C.H. IL-6 mediated alterations on immobile behavior of rats in the forced swim test via ERK1/2 activation in specific brain regions. Behav. Brain Res. 2008, 193:183-191.
63. Wulsin A.C., Herman J.P., Soloman M.B. Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology 2010, 35:1100-1112.